<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642471</url>
  </required_header>
  <id_info>
    <org_study_id>2015-FXY-073</org_study_id>
    <nct_id>NCT02642471</nct_id>
  </id_info>
  <brief_title>Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010)</brief_title>
  <official_title>Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnostic value of sentinel lymph node biopsy in early-stage cervical cancer has been
      well studied. However, there were no randomized controlled study on comparing the long-term
      outcomes of sentinel lymph node biopsy and conventional procedure. The investigators perform
      a phase III, randomized controlled trial to determine whether pelvic lymphadenectomy can be
      replaced by sentinel lymph node biopsy in surgical treatment for patients with early-stage
      cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study comprises two parts: PHENIX-I: To compare the outcomes of managements with and
      without pelvic lymphadenectomy for patients with negative sentinel lymph node; PHENIX-II: To
      compare the outcomes of managements with and without pelvic lymphadenectomy for patients with
      positive sentinel lymph node. Patients with newly diagnosed International Federation of
      Gynecology and Obstetrics (FIGO) stage IA1 (lymphovascular space involvement), IA2, IB1, and
      IB2 cervical cancer are eligible for our study. The tumor diameter should be less than 3cm.
      Sentinel lymph node biopsy will be performed at the beginning of operations. After
      pathological examination of frozen section, patients will be assigned to PHENIX-I or
      PHENIX-II study according to their status of sentinel nodes. In both parts of this trail,
      patients have equal chance to be randomly assigned to experimental arms (radical hysterectomy
      only) and reference arms (radical hysterectomy and pelvic lymphadenectomy).Adjuvant
      treatments will be planned according to postoperative pathological factors. The primary
      objective is disease-free survival at 3 years for PHENIX-I and 2 years for PHENIX-II. The
      secondary end points are overall survival, long-term outcome of sentinel lymph node biopsy
      and the quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival in PHENIX-I</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival in PHENIX-II</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of retroperitoneal node recurrence</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of SLN detection</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of frozen section examination</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomic distribution of SLNs</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1080</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Surgery</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>no systematic pelvic lymphadenectomy</intervention_name>
    <description>systematic pelvic lymphadenectomy is omitted in surgical treatment</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed cervical carcinoma

          -  Histopathology squamous carcinoma, adenocarcinoma or adeno-squamous carcinoma

          -  Original clinical stage must be FIGO (2018) stage IA1 (lymphovascular space
             involvement), IA2, IB1, and IB2

          -  No suspected node should be found on imaging examination (RESIST 1.1)

          -  Age between 18-65

          -  Patients must give signed informed consent

          -  P.S status: 0-1

          -  Estimated survival time ＞ 3 months

          -  Tumor diameter ≤ 3 cm

        Exclusion Criteria:

          -  The presence of uncontrolled life-threatening illness

          -  Receiving other ways of anti-cancer therapy

          -  Investigator consider the patients can't finish the whole study

          -  With normal liver function test (ALT、AST&gt;2.5×ULN)

          -  With normal renal function test (Creatinine&gt;1.5×ULN)

          -  WBC&lt;4,000/mm3 or PLT&lt;100,000/mm

          -  The whole cervix has been occupied by tumor and there is no normal surface left for
             tracer injection

          -  History of severe heart disease or deep venous thrombosis; 4) Presence or history of
             other malignant disease

          -  Gestation or perinatal period

          -  Intention to fertility preservation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihong Liu, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jihong Liu, Ph. D</last_name>
    <phone>86-20-87343102</phone>
    <email>liujih@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Tu, Ph. D</last_name>
    <phone>86-20-87343014</phone>
    <email>tuhua@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jihong Liu, Ph.D.</last_name>
      <phone>86-20-87343102</phone>
      <email>liujih@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hua Tu, Ph.D.</last_name>
      <phone>86-20-87343104</phone>
      <email>tuhua@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>July 11, 2020</last_update_submitted>
  <last_update_submitted_qc>July 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jihong Liu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>sentinel lymph node</keyword>
  <keyword>pelvic lymphadenectomy</keyword>
  <keyword>cervical carcinoma</keyword>
  <keyword>surgery</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

